We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...

Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.

With projections calling for the global biopharmaceuticals market to grow at astable 8.5% compound annual growth rate (CAGR) ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

(Photo by Marla Aufmuth/Getty Images for Pennsylvania Conference For Women ) Barring the recent rise, BMY stock hasn’t fared well, with an 11% decline since January 2023 — falling from levels ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Daiwa America upgraded shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) from a hold rating to a strong-buy rating in a ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Shareholder Yield Investor model based on the ...